Development of a 100 Patient, Multi-Indication Tumor Cell Isolation Cohort for a Biomarker Discovery Study
The client in this case study is a Senior Director leading bioinformatics research and development for a healthcare company whose goal is to improve cancer treatment through diagnostic tools that enable early detection. The primary focus of their research is biomarker discovery for development of liquid biopsy tests in solid tumor indications. Discovery Life Sciences (Discovery) is proud to be a strategic partner to this innovative company since 2016, providing blood, plasma, and dissociated tumor cells (DTCs) samples from various solid tumor indications. This case study chronicles Discovery’s timely provision of tumor cell suspensions from DTCs for this client’s downstream sequencing applications.
Discovery recognizes the sensitive nature of our client’s innovative research and therefore carefully and intentionally protects our client’s identity throughout this case study.